Abstract
Influenza viruses are major human respiratory pathogens that cause high morbidity and mortality worldwide. Currently, prophylactic vaccines and therapeutic antiviral agents are used to prevent and control influenza virus infection. Oseltamivir free base (OSV-FB), a modified generic antiviral drug of Tamiflu (oseltamivir phosphate, OSV-P), was launched in the Republic of Korea last year. Here, we examine the bioequivalence of these two compounds by assessing their antiviral efficacy in infected cells and in a mouse model. It was observed that both antivirals showed comparable efficacy against 11 different influenza A and B viruses in vitro. Moreover, in mice infected with influenza A virus (mouse-adapted A/Puerto Rico/8/34), they showed a dose-dependent therapeutic activity and alleviated infection-mediated reductions in body weight, leading to significantly better survival. There was histopathological disappearance of virus-induced inflammatory cell infiltration of the lung after oral treatment with either antiviral agent (at 10 mg/kg). Pharmacokinetic analysis also exhibited similar plasma concentrations of the active drug, oseltamivir carboxylate, metabolised from both OSV-B and OSV-P. This is the first report showing bioequivalence of OSV-FB to its phosphate salt form in the mouse system. The free base drug has some beneficial points including simple drug formulation process and reduced risk of undesirable cation-phosphate precipitation within solution. The long term stability of OSV-FB requires further monitoring when it is provided as a national stock in readiness for an influenza pandemic.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abed, Y., Goyette, N., and Boivin, G. 2004. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 9, 577–581.
Bischofberger, N., Kim, C., Lew, W., Liu, H., and Williams, M. 1998. Carboxylic compounds. U.S. patent 5,763,483.
FDA 2017. The FDA approves first generic version of widely used influenza drug, Tamiflu. last updated August 04, 2016, available at https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ ucm514854.htm.
Green, M.D., Nettey, H., and Wirtz, R.A. 2008. Determination of oseltamivir quality by colorimetric and liquid chromatographic methods. Emerg. Infect. Dis. 14, 552–556.
Grigoriev, A., Borisova, I., Yaroshenko, I., and Sidorova, A. 2016. In vitro and in vivo stability of oseltamivir within a bioequivalence trial. Anal. Bioanal. Chem. 408, 3891–3897.
Gubareva, L.V., Kaiser, L., and Hayden, F.G. 2000. Influenza virus neuraminidase inhibitors. Lancet 355, 827–835.
Hayden, F.G., Atmar, R.L., Schilling, M., Johnson, C., Poretz, D., Paar, D., Huson, L., Ward, P., and Mills, R.G. 1999. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N. Engl. J. Med. 341, 1336–1343.
Jang, Y., Lee, H.W., Shin, J.S., Go, Y.Y., Kim, C., Shin, D., Malpani, Y., Han, S.B., Jung, Y.S., and Kim, M. 2016. Antiviral activity of KR- 502 targeting nuclear export of influenza B virus ribonucleoproteins. Antiviral. Res. 134, 77–88.
Kerns, E.H. and Di, L. 2008. Drug-like properties: Concepts, structure design and methods from ADME to toxicity optimization, pp. 35–100. Academic Press, Burlington, Massachusetts, USA.
Kim, M., Kim, S.Y., Lee, H.W., Shin, J.S., Kim, P., Jung, Y.S., Jeong, H.S., Hyun, J.K., and Lee, C.K. 2013. Inhibition of influenza virus internalization by (-)-epigallocatechin-3-gallate. Antiviral. Res. 100, 460–472.
Lee, S., Cho, J., Kim, K., Kim, Y., Park, J., and Woo, J. 2016. Solid pharmaceutical composition comprosing oseltamivir free base. PCT Patent WO2106003091.
Lee, S., Lim, D., Lee, E., Lee, N., Lee, H.G., Cechetto, J., Liuzzi, M., Freitas-Junior, L.H., Song, J.S., Bae, M.A., et al. 2014. Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay. J. Med. Chem. 57, 7425–7434.
Li, W., Escarpe, P.A., Eisenberg, E.J., Cundy, K.C., Sweet, C., Jakeman, K.J., Merson, J., Lew, W., Williams, M., Zhang, L., et al. 1998. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42, 647–653.
Ping, J., Dankar, S.K., Forbes, N.E., Keleta, L., Zhou, Y., Tyler, S., and Brown, E.G. 2010. PB2 and hemagglutinin mutations are major determinants of host range and virulence in mouse-adapted influenza A virus. J. Virol. 84, 10606–10618.
Tran, T.T., Kim, M., Jang, Y., Lee, H.W., Nguyen, H.T., Nguyen, T.N., Park, H.W., Le Dang, Q., and Kim, J.C. 2017. Characterization and mechanisms of anti-influenza virus metabolites isolated from the Vietnamese medicinal plant Polygonum chinense. BMC Complement. Altern. Med. 17, 162.
Trussardi, R. 2009. Preparation of oseltamivir phosphate. U.S. Patent 7,531,687.
Wan, S.H., Pentikainen, P.J., and Azarnoff, D.L. 1974. Bioavailability of aminosalicylic acid and its various salts in humans. 3.Absorption from tablets. J. Pharm. Sci. 63, 708–711.
Wu, X., Wu, X., Sun, Q., Zhang, C., Yang, S., Li, L., and Jia, Z. 2017. Progress of small molecular inhibitors in the development of antiinfluenza virus agents. Theranostics 7, 826–845.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplemental material for this article may be found at http://www.springerlink.com/content/120956.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Shin, J.S., Ku, K.B., Jang, Y. et al. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate. J Microbiol. 55, 979–983 (2017). https://doi.org/10.1007/s12275-017-7371-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-017-7371-x